Show simple item record

dc.contributor.authorPeart, J
dc.contributor.authorHeadrick, J
dc.contributor.authorGross, G
dc.contributor.editorDr. R. A. Walsh (Editor-in-Chief)
dc.date.accessioned2017-05-03T16:55:34Z
dc.date.available2017-05-03T16:55:34Z
dc.date.issued2006
dc.date.modified2009-09-15T07:36:35Z
dc.identifier.issn0022-2828
dc.identifier.doi10.1016/j.yjmcc.2006.06.045
dc.identifier.urihttp://hdl.handle.net/10072/22228
dc.description.abstractChronic opioid preconditioning confers a pronounced and prolonged cardioprotective phenotype, existing at least 24 hours beyond opioid drug withdrawal. This study aims to delineate both the trigger and mediation phase of this cardioprotective state. To this end, we employed an isolated, perfused murine heart model of ischemia reperfusion. Following 25 min ischemia and 45 min reperfusion, placebo-treated hearts exhibited a pronounced degree of contractile dysfunction (EDP, 32 ᠳ mmHg; RPP, 40 ᠴ% baseline). In stark contrast, chronic morphine-treated (CMP) hearts (75 mg pellet, 5 days) displayed a significant recovery of RPP (83 ᠳ%) and an almost complete return of EDP. As expected, co-administration of opioid antagonist, naloxone, via osmotic minipump for 5 days prevented the initiation ("trigger" phase), and thus, protection of CMP (RPP, 46 ᠲ%). Moreover, 5 day infusion of the primary morphine metabolites, morphine-3-glucuronide and morphine-6-glucuronide, failed to induced any form of cardioprotection, suggesting that neither the mu-opioid receptor nor metabolites are involved. Concurrent infusion of the PKA inhibitor, PKI, during the activation phase failed to abolish the CMP-mediated protection (69 ᠵ% RPP). Interestingly, naloxone, administered pre-and post-ischemia (the "mediation" phase), following 5 days of morphine exposure, failed to modify the CMP-induced phenotype, while PKI completely abolished CMP protection, with no effect on placebo-treated hearts. These data offer an insight into the genesis of CMP in the murine heart, whereby the trigger phase is opioid receptor-dependent and PKA-independent, whereas the mediation phase is independent of opioid receptor activation and is PKA-dependent.
dc.description.publicationstatusYes
dc.languageEnglish
dc.language.isoeng
dc.publisherAcademic Press
dc.publisher.placeUnited Kingdom
dc.publisher.urihttp://www.sciencedirect.com/science/journal/00222828
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom743
dc.relation.ispartofpageto744
dc.relation.ispartofissue4
dc.relation.ispartofjournalJournal of Molecular and Cellular Cardiology
dc.relation.ispartofvolume41
dc.rights.retentionY
dc.subject.fieldofresearchCardiovascular medicine and haematology
dc.subject.fieldofresearchCardiology (incl. cardiovascular diseases)
dc.subject.fieldofresearchMedical physiology
dc.subject.fieldofresearchBiochemistry and cell biology
dc.subject.fieldofresearchcode3201
dc.subject.fieldofresearchcode320101
dc.subject.fieldofresearchcode3208
dc.subject.fieldofresearchcode3101
dc.titleTrigger and mediation phase of chronic opioid preconditioning are mediated via divergent pathways
dc.typeJournal article
dc.type.descriptionC3 - Articles (Letter/ Note)
dc.type.codeC - Journal Articles
gro.facultyGriffith Health, School of Medical Science
gro.date.issued2006
gro.hasfulltextNo Full Text
gro.griffith.authorHeadrick, John P.
gro.griffith.authorPeart, Jason N.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record